The challenges around implementing AI are real: 77% of pharma executives intend to rethink their data strategies, and only 35% believe their current strategies are designed to create competitive differentiation, according to ZS research.
They’re looking to construct robust “moats” with their data—borrowing a term from business strategy. In this world, data is a driver of business growth, focusing on the advantage that comes from continuously learning and adapting from its possibilities.
Yet to use data as a growth driver in the age of AI, we must address a fundamental question: Where does data create unique value? In pharma and life sciences this means looking in each business domain, especially with an eye toward gen AI’s ability to combine previously untapped unstructured data with traditional data sources. Click below to continue reading.